questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the cap mechanism in the Voluntary Scheme for Branded Medicines Pricing and Access on (a) levels of investment in late stage clinical trials and (b) decisions taken by pharmaceutical companies regarding (i) whether and (ii) when to launch medicines in the UK.
answerText: The Government has assessed the link between the cap mechanism in our medicine pricing schemes and various kinds of investment in our impact assessment of recent updates to the statutory scheme for branded medicines pricing, which operates alongside the v...
heading: Voluntary Scheme for Branded Medicines Pricing and Access